Is Thymosin Alpha-1 Legal in Minnesota?
HealthRX.com
Thymosin alpha-1 has no FDA approval and no clear compounding path
Key numbers
- 4 yes and 17 noFDA advisory committee vote on thymosin alpha-1 on December 4, 2024: yes and no votesSource: fda.gov, as cited Nov 7, 2026
- 1.6 mgStrength of the finished thymosin alpha-1 injection sold outside the US (Zadaxin brand)Source: fda.gov, as cited Nov 7, 2026
- 28-amino-acidLength of the thymosin alpha-1 peptide chain, in amino acidsSource: fda.gov, as cited Nov 7, 2026
At a glance
- FDA approval / None; no US application found [2]
- Orphan designations / Four, a separate process from approval [2]
- State-licensed pharmacy list / In none of the three categories; list updated May 14, 2026 [3]
- Outsourcing facility list / Category 3, nominated without adequate support [4]
- Advisory committee / Voted 4 yes, 17 no on December 4, 2024 [5]
- HHS draft peptide policy / Not among the six named peptides [6]
- Approved outside US / Italy, India, Hong Kong; two developer-tied reviews say 30 or more countries [2][7][8]
- Minnesota law / Chapter 151 has sections on compounding (151.253) and legend drugs (151.37); its section headings do not name thymosin alpha-1 [1]
What is thymosin alpha-1, and is it FDA-approved?
Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide with an acetylated N-terminal end, originally isolated from thymosin fraction 5, a thymus extract; thymalfasin is the synthetic version, and Zadaxin is the brand of the finished 1.6 mg injection sold outside the US [2]. It is described as an immune modulator that augments T-cell function [9].
It has no FDA approval. A Drugs@FDA search found no US application for it, and its four US orphan drug designations come from a separate process and are not an approval [2].
Where does it sit in FDA's compounding rules?
On FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026), thymosin alpha-1 appears in none of the three categories [3]. It was previously in category 2, the tier for substances FDA believes may present significant safety risks, and now sits in the nominated-but-withdrawn table after the nominators withdrew; FDA's concerns about immunogenicity for certain routes, peptide impurities, and inadequate safety information remain posted [10]. FDA's category 1 policy does not apply to it [3].
On FDA's separate list for outsourcing facilities (updated March 21, 2025), it is in category 3, nominated without adequate support [4]. FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no on December 4, 2024, on both thymosin alpha-1 free base and thymosin alpha-1 acetate, and FDA proposed that the substance not be added to the pharmacy bulks list [5]. It is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [6].
Questions worth asking
What does Minnesota's pharmacy law say?
Minnesota's chapter 151 (the Pharmacy Practice and Wholesale Distribution Act) includes section 151.253 on compounding and section 151.37 on legend drugs and who may prescribe and possess them. Its table of sections does not name thymosin alpha-1 or peptides, so the federal status above is what determines how the substance is treated [1].
Frequently asked questions
Is thymosin alpha-1 FDA-approved?
Can a state-licensed pharmacy compound thymosin alpha-1?
Is thymosin alpha-1 on the WADA prohibited list?
Why does FDA have safety concerns about compounded thymosin alpha-1?
References
Show all 11 referencesHide references
- Ch. 151 MN Statutes.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
- Tuthill C. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing. Ann N Y Acad Sci. 2007;1112:351-6.
- Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- World Anti-Doping Agency.